This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

Herein are reported modified mammalian cells wherein the expression of the MYC gene and one or more of the BAK, BAX, SIRT-1 and ICAM-1 genes has been reduced or eliminated as well as methods for the recombinant production of a heterologous polypeptide using a modified mammalian cell according to the current invention. Further reported are use of the reduction of the expression of the genes for increasing volumetric productivity, increasing cell volume, increasing viability and increasing the possible cultivation time without cell split.

The present invention relates to, inter alia, safe and effective doses of a beta-lactamase for, e.g. microbiome protection.

Provided herein are compositions and methods for adoptive cell therapy comprising engineered immune cells that express an antigen-targeted chimeric antigen receptor and a prodrug converting enzyme for the treatment of inflammation, inflammatory diseases, or pathogenic infections.

An electrochemical method is provided for in-vitro determination of the presence of bacteria producing lactamases, in a sample that may contain such bacteria.

This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

The present invention relates to, inter alia, safe and effective doses of a beta-lactamase for, e.g. microbiome protection.

The present invention provides a cell-based assay for measuring T cell activation mediated by a T cell -dependent bispecific antibody (TDB). In some aspects, the assay is useful for detecting a TDB in a composition, quantitating the amount of TDB in a composition, determining the potency and/or specificity of a TDB, or determining if a population of cells expresses a target antigen. Compositions and kits are also contemplated.

Provided herein are microorganisms engineered with hybrid receptors and genetic circuits. Also provided are hybrid receptors having a CqsS polypeptide and a heterologous histidine kinase domain of a two-component system. Methods for using engineered microorganisms to sense and destroy pathogens (e.g., Vibrio cholerae) are also provided.

This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).